EGFR and neoplasm: Taken together, these data indicate that 1,25(OH)2D3 significantly induced the expression of hCAP18/LL-37 in tumor tissue, while hCAP18/LL-37 decreased the antitumor activity of 1,25(OH)2D3 partly by activating the EGFR/HER2/Akt signaling pathway.